Posted by Michael Wonder on 13 Jul 2017
Amgen and Allergan to discuss data supporting biologics license application for ABP 215, a biosimilar candidate to Avastin (bevacizumab)
13 July 2017 - First Amgen and Allergan oncology biosimilar candidate to be reviewed by U.S. FDA Advisory Committee
Amgen and Allergan today announced that the Companies will discuss data supporting the ABP 215 biologics license application with the Oncologic Drugs Advisory Committee of the U.S. FDA.
ABP 215 is a biosimilar candidate to Avastin (bevacizumab) and is the first bevacizumab biosimilar candidate to be considered by the FDA.
